Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
Clinical trial NCT04740307 · COMPLETED
Trial details
- NCT number
- NCT04740307
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-16
- Primary completion
- 2025-07-29
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.